Current Clinical Trials
To be conducted by Dr Mili Shah and Dr Victoria Potter of King’s College Hospital, London, and Professor Robert Wynn of Royal Manchester Children’s Hospital. This upcoming study will focus on the use of expanded cord blood stem cells, alongside granulocytes (a type of white blood cell) in both adults and children with high-risk […]
Read full story
Do you have low/intermediate risk MDS? Find out more about REPAIR-MDS, a ground breaking clinical trial that could improve MDS symptoms and overall quality of life.
Read full story
The AMMO trial will test a new drug called ASTX727 to see how effective it is at treating and extending/improving the lives of people with MDS/MPN Overlap Syndromes, such as CMML. The trial is a comparison of response to treatment of patients taking ASTX727 versus best supportive care.
Read full story
- SUB-TYPE OF MDS: All subtypes of MDS
- SEVERITY OF MDS: Low Risk MDS
- SUB-TYPE OF MDS: All subtypes of MDS.
- SEVERITY OF MDS: High Risk MDS and Acute myeloid leukaemia.
- NAME OF DRUG: CCS-1477
- SUB-TYPE OF MDS: All subtypes of MDS.
- SEVERITY OF MDS: Intermediate or High Risk MDS and Acute myeloid leukaemia.
- NAME OF DRUG: PDR001, MBG453
- SUB-TYPE OF MDS: All Subtypes
- SEVERITY OF MDS: Intermediate, High or Very High Risk
- NAME OF DRUG: Venetoclax
- SUB-TYPE OF MDS: Patients with relapsed/refractory AML or AML secondary to myeloproliferative neoplasm.
- SEVERITY OF MDS: Intermediate, High or Very High Risk
- NAME OF DRUG: KRT-232
- SUB-TYPE OF MDS: Patients with MDS or CMML who have relapsed from or are refractory to previous therapy
- SEVERITY OF MDS: Intermediate, High or Very High Risk
- NAME OF DRUG: EP0042
- SUB-TYPE OF MDS: MDS patients and Chronic Myelomonocytic leukaemia -2 patients who require first-line treatment
- SEVERITY OF MDS: Intermediate, High or Very High Risk
- NAME OF DRUG: Sabatolimab (MBG453)
